Global Hepatitis B Therapeutics Market Forecast (2018-2022) with Bristol-Myers Squibb, F. Hoffmann-La Roche, Gilead, GlaxoSmithKline, and Merck Sharp & Dohme Leading the Competition - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jan 2, 2019--The “Global Hepatitis B Therapeutics Market 2018-2022” report has been added to ResearchAndMarkets.com’s offering.
The global hepatitis B therapeutics market is fragmented, as many pharmaceutical companies are developing drugs for the treatments of hepatitis B. Also, several companies are forming collaborations to increase their research toward the hepatitis B drug development.
These types of strategic collaboration between the pharmaceutical companies will propel the hepatitis B therapeutics development and lead to increase the growth of the market during our forecast period. This will boost the growth of the hepatitis B therapeutics market at a CAGR of over 2% during the forecast period.
Increasing prevalence of hepatitis B in infants
The increase in the prevalence of hepatitis B in infants, the companies are developing various drugs against hepatitis B virus. This leads to an increase in the global market during the forecast period.
Low accessibility due to high cost of hepatitis B treatment
One of the major problems from the treatment of hepatitis B is that not all the approved drugs are accessible to people and some are not affordable. Therefore, low accessibility due to the high cost of hepatitis B treatment is one the biggest challenges for the goal aiming to eliminate hepatitis B during our forecast period.
Key PlayersBristol-Myers Squibb F. Hoffmann-La Roche Gilead GlaxoSmithKline Merck Sharp & Dohme
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPEMarket ecosystem Market characteristics Market segmentation analysis
PART 05: MARKET SIZINGMarket definition Market sizing 2017 Market size and forecast 2017-2022
PART 06: FIVE FORCES ANALYSIS
PART 07: PIPELINE LANDSCAPE
PART 08: MARKET SEGMENTATION BY APPLICATIONSegmentation by application Comparison by application Drugs - Market size and forecast 2017-2022 Vaccines - Market size and forecast 2017-2022 Market opportunity by application
PART 09: CUSTOMER LANDSCAPE
PART 10: REGIONAL LANDSCAPEGeographical segmentation Regional comparison Americas - Market size and forecast 2017-2022 EMEA - Market size and forecast 2017-2022 APAC - Market size and forecast 2017-2022 Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
PART 13: MARKET TRENDSStrategic alliances Strong pipeline New technological advancements
PART 14: VENDOR LANDSCAPEOverview Landscape disruption
PART 15: VENDOR ANALYSISVendors covered Vendor classification Market positioning of vendors Bristol-Myers Squibb F. Hoffmann-La Roche Gilead GlaxoSmithKline Merck Sharp & Dohme
For more information about this report visit https://www.researchandmarkets.com/research/dcgndb/global_hepatitis?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190102005376/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Infectious Diseases Drugs,Liver and Kidney Disorders Drugs
INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 01/02/2019 10:12 AM/DISC: 01/02/2019 10:12 AM